Full Text View
Tabular View
No Study Results Posted
Related Studies
Framing Messages for Smoking Cessation With Bupropion - 6
The recruitment status of this study is unknown because the information has not been verified recently.
Verified February 2005 by National Institute on Drug Abuse (NIDA).   Recruitment status was  Active, not recruiting

First Received on March 1, 2005.   Last Updated on November 3, 2005   History of Changes
Sponsor: National Institute on Drug Abuse (NIDA)
Information provided by: National Institute on Drug Abuse (NIDA)
ClinicalTrials.gov Identifier: NCT00104598
  Purpose

This is a randomized study of message framing in individuals beginning a smoking cessation program utilizing bupropion SR and brief counseling, videos, and pamphlets.


Condition Intervention
Tobacco Use Disorder
Drug: Bupropion

Study Type: Interventional
Study Design: Intervention Model: Parallel Assignment
Primary Purpose: Treatment
Official Title: Framing Messages for Smoking Cessation With Buproprion

Resource links provided by NLM:


Further study details as provided by National Institute on Drug Abuse (NIDA):

Primary Outcome Measures:
  • Medication compliance
  • Smoking Cessation

Estimated Enrollment: 252
Study Start Date: September 2000
  Eligibility

Ages Eligible for Study:   18 Years to 70 Years
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   Yes
Criteria

Exclusion Criteria:

  • Pregnant or nursing women, or women of child-bearing potential who are not using an adequate method of contraception
  • Psychiatric illnesses requiring psychotropic medications (i.e., psychosis, major depression, mania), or the presence of suicidality or homocidality
  • Current use of nicotine replacement therapies (i.e., nicotine patch, gum, or lozenges, nasal spray, or inhaler), bupropion (Zyban, Wellbutrin), or marijuana or current participation in another smoking cessation treatment
  • Presence of unstable medical conditions (i.e., cardiac, hepatic, renal disease, diabetes mellitus) that would make a trial of bupropion SR hazardous
  • Have taken monoamine oxidase inhibitors or metoprolol succinate within the past six weeks
  • History of anorexia nervosa or bulimia
  • Previous hypersensitivity to bupropion
  • History of alcohol or other drug dependence in the past one year
  • History of seizure disorder of any etiology (i.e., brain tumor, traumatic brain injury, substance-induced seizures, etc.)
  • Any finding that in the view of the principal investigator would compromise the subject's ability to fulfill the protocol visit schedule and visit requirements or put the subject at risk
  • Sharing home or work environment with current or past participant
  • No couples or participants who see each other every day
  Contacts and Locations
Please refer to this study by its ClinicalTrials.gov identifier: NCT00104598

Locations
United States, Connecticut
Substance Abuse Treatment Unit
New Haven, Connecticut, United States, 06519
Sponsors and Collaborators
Investigators
Principal Investigator: Stephanie O'Malley, Ph.D. Substance Abuse Treatment Unit
  More Information

No publications provided

ClinicalTrials.gov Identifier: NCT00104598     History of Changes
Other Study ID Numbers: NIDA-13334-6, P50-13334-6
Study First Received: March 1, 2005
Last Updated: November 3, 2005
Health Authority: United States: Federal Government

Additional relevant MeSH terms:
Tobacco Use Disorder
Substance-Related Disorders
Mental Disorders
Bupropion
Antidepressive Agents, Second-Generation
Antidepressive Agents
Psychotropic Drugs
Central Nervous System Agents
Therapeutic Uses
Pharmacologic Actions
Dopamine Uptake Inhibitors
Dopamine Agents
Neurotransmitter Agents
Molecular Mechanisms of Pharmacological Action
Neurotransmitter Uptake Inhibitors
Physiological Effects of Drugs

ClinicalTrials.gov processed this record on February 12, 2012